Conjunctivitis Clinical Trial
Official title:
A Randomized, Placebo-controlled, Double-masked Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Vernal Keratoconjunctivitis
To investigate the efficacy and safety of FK506 ophthalmic suspension on eye symptoms in patients with vernal keratoconjunctivitis
0.1% FK506 ophthalmic suspension were administered twice-a-day to patients with vernal keratoconjunctivitis in whom treatment with topical anti-allergic agents had been ineffective. The primary efficacy endpoint was the mean change from the baseline (before the treatment)in total score for objective clinical signs at the final observation. The safety of FK506 ophthalmic suspension was also investigated. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00770315 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
|
Phase 3 | |
| Completed |
NCT00783198 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06229379 -
The Effects of a Large Language Model on Clinical Questioning Skills
|
N/A | |
| Not yet recruiting |
NCT03631108 -
Feasibility Study and Preliminary Application Study on Iris OCTA
|
||
| Completed |
NCT01028027 -
Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
|
Phase 3 | |
| Completed |
NCT00978029 -
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
|
Phase 2 | |
| Completed |
NCT00562159 -
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT00550550 -
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
|
Phase 3 | |
| Withdrawn |
NCT02795273 -
Efficacy and Safety of Grass-SPIRE Registration Study
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT01600365 -
Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
|
Phase 3 | |
| Completed |
NCT00567918 -
Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis
|
Phase 3 | |
| Completed |
NCT04374656 -
Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
|
||
| Completed |
NCT03753893 -
Ocular Manifestations in Rheumatic Diseases
|
||
| Completed |
NCT02472223 -
Reducing Adenoviral Patient Infected Days
|
N/A | |
| Completed |
NCT00001734 -
Screening for NEI Clinical Studies
|
N/A | |
| Completed |
NCT00623701 -
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
|
Phase 3 | |
| Completed |
NCT00581542 -
Moxifloxacin vs. Polytrim for Conjunctivitis
|
Phase 4 | |
| Completed |
NCT04287608 -
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
|
||
| Completed |
NCT04984941 -
Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
|
||
| Completed |
NCT01385371 -
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
|
Phase 3 |